Introduction to IFPMA

Committed To a Healthier Future

June 2018



International Federation
of Pharmaceutical
Manufacturers & Associations



We are the industry interlocutor and partner for intergovernmental organizations







IFPMA has a consultative status with the united nations and specialized agencies, including:

- World health organization (WHO)
- World intellectual property organization (WIPO)
- United nations conference on trade and development (UNCTAD)
- United nations economic and social council (ECOSOC)

And a formal relationship with:

- World bank
- World trade organization (WTO)

New industry spokesperson beyond Geneva







- Organization for Economic Cooperation and Development (OECD)
- G7
- G20



IFPMA delivers high-level messages at key meetings such as:

- Consultation on sustainable access to innovative medicines.
- Fair pricing forum in Amsterdam
- B20 health summit in Berlin

Section 1 IFPMA Governance





IFPMA members | Companies
















































































IFPMA members | Associations





IFPMA Presidency 2017-2018



Mr Ian C Read
President
Pfizer



Dr Isao TeshirogiVice President
Shionogi & Co



Dr Severin SchwanVice President
Roche Group



CEO Steering Committee

- President and Vice-Presidents of IFPMA (lan Read, Severin Schwan, Isao Teshirogi)
- Chairman of the Board PhRMA and Chair of PhRMA International Comm (Bob Bradway, Olivier Brandicourt)
- President of EFPIA (Stefan Oschmann)
- President of JPMA (George Nakayama)
- Representative of SME Member Companies (Jean-Christophe Tellier)
- Director-General of IFPMA (Thomas Cueni)

Members is advisory capacity:

- Director General of EFPIA (Nathalie Moll)
- Director General of JPMA (Akihiko Matsubara)
- President of PhRMA (Stephen Ubl)
- Chairperson of the IFPMA Council (Jeff May)




IFPMA Council

- Consist of delegates from Member Associations and Member Companies
- Powers & Functions (Article 14 of Statutes):
 - Prepare the agenda for meetings of the assembly
 - Provisionally admit new members
 - Submit reports of the activities of the IFPMA
 - Approve the annual accounts
 - Approve the federation's budget
 - Approve any alterations or amendments to the guidelines
 - •
- Current Chair & Vice-Chairs: Jeff May (MSD), Philippe Lamoureux (LEEM), Haruhiko Hirate (Takeda
- Meetings in 2018: May 17-18 (Geneva) & December 03-04 (Geneva)



2018 Committee Structure





Section 2 IFPMA Strategic Framework





Bridge between the industry and global health stakeholders

IFPMA is a **strong**, **assertive** voice for the industry's value proposition, with a portfolio of constructive initiatives, positioning the industry as thought leaders and solutions partners.



IFPMA brings **insights** on political and policy trends, and external stakeholder perspectives to its members.



Bridge between the industry and global health stakeholders

Vision & Mission

Vision

IFPMA is the voice for biopharmaceutical innovation and health progress around the world.

Mission

To promote policies, dialogues and initiatives that encourage the discovery of and access to medicines and vaccines globally.

Who We Are

Thought Leader

Share expertise in key for aabout innovation, regulatory and health policy issues.

Solutions Partner

Tackle health challenges responsibly and collaboratively, to improve health outcomes.

Convener

Build bridges within and across sectors to advance mutual goals and gain trust.



Bridge between the industry and global health stakeholders

Ethics and Business Integrity

Advance Sustainable Health Systems Promote policies & dialogue to advance sustainable financing and health system reforms, including access & availability of medicines & vaccines worldwide.

Advocate for policies that enable & recognize the value of science and biopharmaceutical innovation.

"Global Health Progress"

Foster a Sound
Biopharmaceutical
Innovation
Ecosystem

Champion
Solutions for
Global Health
Challenges
Build

Build bridges amongst diverse actors to champion solutions for improving public health and patient outcomes.



Section 3 IFPMA Strategic Partnerships





Access Accelerated



A first-of-its-kind, global multi-stakeholder initiative of 23 biopharmaceutical companies advancing access to NCD treatment and care in low and lower-middle income countries to:



Advance **sustainable progress** on NCDs and the SDGs



Leverage the power and expertise of industries



Partner with others to understand and address systematic barriers




Improve outcomes for **patients**




AMR Industry Alliance



The AMR Industry Alliance is the largest private sector coalition set up to provide sustainable solutions to curb antimicrobial resistance, with over a 100 research-based pharmaceutical, generics, biotech and diagnostic companies and associations joining forces.



1st Progress Report: January 2018





Pat-INFORMED



Pat-INFORMED is an international platform seeking to facilitate national and international drug procurement agencies to access a basic body of patent information. A voluntary initiative with the participation of twenty-one of the world's leading research-based biopharmaceutical companies.

Memorandum of understanding WIPO-IFPMA

- Signed in October 2017
- Full launch of database in September 2018





BILL & MELINDA
GATES foundation





African Global Health Leaders Fellowship Program



The African Global Health Leaders Fellowship program established with The Centre on Global Health Security at Chatham House and the Global Health Centre at the Graduate Institute aims at supporting the development of the next generation of public health leaders in Africa.

Memorandum of understanding WIPO-IFPMA

- Signed in January 2018, to support 10 fellows over 2 years
- Fellows started in October 2018







Learn more and stay connected

in linkedin.com/company/ifpma/

twitter.com/IFPMA

ifpma.org

